FDA Approves First Dabigatran Reversal Agent (FREE)

By Amy Orciari Herman Edited by Susan Sadoughi, MD The FDA on Friday granted accelerated approval for idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa) in emergency situations. Idarucizumab, an injectable monoclonal antibody fragment, binds to dabigatran and thereby neutralizes its effect.Approval was based on three trials …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news